These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 16714061

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y, Mashav N, Henis O, Swartzon M, Arbel Y, Justo D.
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Guidelines for treating cardiac manifestations of organophosphates poisoning with special emphasis on long QT and Torsades De Pointes.
    Bar-Meir E, Schein O, Eisenkraft A, Rubinshtein R, Grubstein A, Militianu A, Glikson M, CBRN Medical Branch, Medical Corps, Israel Defense Forces.
    Crit Rev Toxicol; 2007 Mar; 37(3):279-85. PubMed ID: 17453935
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA, Kluger J, White CM.
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [Abstract] [Full Text] [Related]

  • 49. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y, Swartzon M, Justo D.
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies.
    Shryock JC, Song Y, Wu L, Fraser H, Belardinelli L.
    J Electrocardiol; 2004 Apr; 37 Suppl():34-9. PubMed ID: 15534790
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A, Arnaoutoglou C, Krommydas A, Papanikolaou G, Tsiptses K, Chrisopoulos C, Kirpizidis C.
    Cardiol J; 2009 Apr; 16(2):172-4. PubMed ID: 19387967
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Points to consider emerging from a mini-workshop on cardiac safety: assessing torsades de pointes liability.
    Bass A, Valentin JP, Fossa AA, Volders PG.
    J Pharmacol Toxicol Methods; 2007 Apr; 56(2):91-4. PubMed ID: 17707127
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.